Q3 2024 Natera Inc Earnings Call Transcript
Key Points
- Natera Inc (NTRA) reported a record revenue of $439.8 million for Q3 2024, marking a 64% increase from the previous year.
- The company achieved a significant milestone by generating $34.5 million in cash this quarter, after breaking even on cash for a couple of quarters.
- Gross margins reached a record 62% in Q3, driven by strong ASPs and execution on cost projects.
- Natera Inc (NTRA) raised its revenue guidance for the year to $1.61 billion to $1.64 billion, implying about 50% revenue growth for the full year.
- The company has seen strong demand for its new fetal rhd test, launched at a critical time for the prenatal community.
- Despite the strong financial performance, the company faces ongoing litigation expenses and non-cash charges related to stock-based compensation.
- There is potential for quarter-to-quarter volatility in ASPs, which could impact financial performance.
- The company is cautious about the impact of weather events, such as hurricanes, which could affect future quarters.
- Natera Inc (NTRA) continues to face challenges with insurance payers, including prior authorization and medical records requests.
- The company acknowledges that the growth rates may become challenging as the base business becomes larger, potentially impacting future growth expectations.
Welcome to Nateras 2024 3rd quarter. Financial results conference call. At this time, all participants are in a listen-only mode following management's prepared remarks. We will hold a Q&A session to ask a question at that time. Please press star followed by one on your touchtone phone.
If anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this conference call is being recorded today. November 12th 2024.
I would now like to turn the conference call over to Michael Brophy, Chief Financial Officer. Please go ahead.
Thanks operator. Good afternoon. Thank you for joining our conference call to discuss the results of our third quarter of 2024 on the line. I am joined by Steve Chapman, our CEO and Alex Selectin, General Manager of oncology and Chief Medical Officer, Salman Moscovitch, President Clinical Diagnostics couldn't be here today but will be joining us again next quarter.
Today's conference call is being broadcast
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
